SOURCE: AMICUS THERAPEUTICS What: After reporting additional late stage trial data and ahead of learning that a key European advisory committee had voted in support of its lead drug, shares of Amicus Therapeutics shot 23.4% higher in March, according to data from S&P Global Market Intelligence .
